The stock is likely to react negatively to the clinical trial failure and R&D shutdown. However, the significant cost savings, strong cash balance, and ongoing strategic review (potentially leading to a sale) could limit downside or create a speculative opportunity. Traders should monitor for updates on the strategic review and the company's ability to generate the projected $60-70 million in annualized cash flow from YUPELRI.
TBPH drugs
TBPH drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $13.96entry
- T+1 · 9mo ago −2.11%α −2.87% · $13.67
- T+5 · 8mo ago +0.50%α +0.98% · $14.03
- T+20 · 8mo ago +16.26%α +20.66% · $16.23
- T+60 · 6mo ago +16.48%α +6.16% · $16.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, prompting the company to wind down the program. In response, the company is restructuring, cutting costs by ~60% ($70M), reducing its workforce by ~50%, and accelerating a strategic review that could include a sale. Despite the setback, the company maintains a strong cash position (~$400M expected) and a profitable commercial product, YUPELRI.
Key Financial Metrics
Key Facts
- Phase 3 CYPRESS study for ampreloxetine failed to meet primary endpoint (OHSA Composite Score).
- Company is winding down the ampreloxetine program and its entire R&D function.
- Organizational restructuring will reduce operating expenses by ~60% (~$70 million) and impact ~50% of the workforce.
- Strategic Review Committee is accelerating its review of alternatives to maximize shareholder value, including a potential sale of the company.
- Company expects ~$400 million in cash by end of Q1 2026, driven by recent milestone payments.
- YUPELRI net sales grew 12% YoY in FY 2025 to $266.6 million, and the company expects a $100 million TRELEGY milestone in 2026.
Financial Impact
Cost savings of ~$70 million annually, one-time severance costs of $5-7 million, and a $326.5 million cash balance as of year-end 2025.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| YUPELRI | $266.6M | +12.0% |
Risk Factors
- The failure of the CYPRESS study eliminates a key future growth driver, leaving the company reliant on YUPELRI and potential milestones.
- The strategic review may not result in a transaction, leaving the company as a smaller, less diversified entity.
- The restructuring could lead to loss of key talent and operational disruption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-022572 |
| Document: tm267846d1_8k.htm | 0001104659-26-022572 |
| Document: 0001104659-26-022572-index-headers.html | 0001104659-26-022572 |
| Document: 0001104659-26-022572.txt | 0001104659-26-022572 |
Track record
12 reports on TBPH
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +0.89% at T+20 after the Aug 10, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
- Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
- Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
- Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
- Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
- Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
- Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers